Q3 Earnings Estimate for RNTX Issued By HC Wainwright

Rein Therapeutics Inc. (NASDAQ:RNTX) – Equities researchers at HC Wainwright issued their Q3 2025 EPS estimates for Rein Therapeutics in a research report issued on Monday, September 22nd. HC Wainwright analyst B. Folkes anticipates that the company will post earnings per share of ($0.22) for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Rein Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Rein Therapeutics’ Q4 2025 earnings at ($0.27) EPS and FY2025 earnings at ($1.01) EPS.

Separately, Brookline Capital Management lowered shares of Rein Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 19th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Rein Therapeutics Stock Performance

Shares of NASDAQ:RNTX opened at $1.20 on Wednesday. The firm has a market cap of $27.86 million, a PE ratio of -0.44 and a beta of 1.13. The firm’s 50 day simple moving average is $1.23 and its 200-day simple moving average is $1.58. Rein Therapeutics has a one year low of $1.04 and a one year high of $4.40.

Rein Therapeutics (NASDAQ:RNTX) last issued its earnings results on Thursday, August 14th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06).

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Cable Car Capital LP acquired a new position in shares of Rein Therapeutics in the second quarter worth about $588,000. Geode Capital Management LLC acquired a new position in shares of Rein Therapeutics in the second quarter worth about $344,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Rein Therapeutics during the second quarter worth about $68,000. Voss Capital LP purchased a new stake in shares of Rein Therapeutics during the second quarter worth about $2,007,000. Finally, BIOS Capital Management LP purchased a new stake in shares of Rein Therapeutics during the second quarter worth about $2,367,000. Institutional investors and hedge funds own 90.89% of the company’s stock.

About Rein Therapeutics

Rein Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.